Ken Griffin Biotechnology

Citadel Advisors LLC

  • $618 Billion
  • Q3 2025

Stock List

Stock Option Type Value Options Held Last Trade Trade History
COGT
Cogent Biosciences, Inc.
CALL
$173,000
12.1K
Q3 2025
Added 168.47%
CADL
Candel Therapeutics, Inc.
PUT
$171,000
33.3K
Q3 2025
New holding
CRBU
Caribou Biosciences, Inc.
PUT
$171,000
73.7K
Q3 2025
Added 10.37%
DNLI
Denali Therapeutics Inc.
CALL
$168,000
11.6K
Q3 2025
Reduced 44.9%
SGMO
Sangamo Therapeutics, Inc
PUT
$165,000
248K
Q3 2025
Added 518.87%
RGNX
Regenxbio Inc.
CALL
$161,000
16.7K
Q3 2025
Reduced 80.98%
IMAB
I Mab
PUT
$159,000
42.3K
Q4 2024
Reduced 99.05%
ADGI
Adagio Therapeutics, Inc.
CALL
$158,000
47.9K
Q1 2025
Added 297.73%
TNYA
Tenaya Therapeutics, Inc.
CALL
$158,000
103K
Q2 2025
New holding
SGMO
Sangamo Therapeutics, Inc
CALL
$155,000
233K
Q3 2025
Added 518.87%
ENTA
Enanta Pharmaceuticals Inc
PUT
$143,000
12K
Q2 2025
Reduced 8.91%
MGTX
Meira G Tx Holdings PLC
PUT
$140,000
17.1K
Q3 2025
Added 1.61%
VYGR
Voyager Therapeutics, Inc.
CALL
$139,000
30.1K
Q3 2025
Added 104.58%
ABUS
Arbutus Biopharma Corp
CALL
$138,000
30.6K
Q3 2025
Added 61.04%
CTMX
Cytom X Therapeutics, Inc.
PUT
$138,000
43.5K
Q3 2025
Added 2005.55%
OCGN
Ocugen, Inc.
PUT
$136,000
83.8K
Q3 2025
Added 160.49%
VTYX
Ventyx Biosciences, Inc.
CALL
$136,000
43.8K
Q3 2025
Added 6.49%
LXRX
Lexicon Pharmaceuticals, Inc.
PUT
$133,000
96.6K
Q3 2025
New holding
VNDA
Vanda Pharmaceuticals Inc.
PUT
$129,000
25.9K
Q3 2025
Added 78.49%
CHRS
Coherus Bio Sciences, Inc.
CALL
$128,000
78.3K
Q3 2025
Added 147.08%
HUMA
Humacyte, Inc.
PUT
$127,000
73.3K
Q3 2025
Added 42.93%
OLMA
Olema Pharmaceuticals, Inc.
PUT
$125,000
13K
Q3 2025
Reduced 27.59%
MIST
Milestone Pharmaceuticals Inc.
PUT
$124,000
62.6K
Q3 2025
New holding
CCCC
C4 Therapeutics, Inc.
PUT
$120,000
54.4K
Q3 2025
New holding
ERAS
Erasca, Inc.
CALL
$119,000
54.8K
Q3 2025
New holding
PBYI
Puma Biotechnology, Inc.
CALL
$119,000
23.3K
Q2 2025
New holding
MREO
Mereo Biopharma Group PLC
PUT
$110,000
55.3K
Q3 2025
Added 316.96%
TERN
Terns Pharmaceuticals, Inc.
PUT
$107,000
14.2K
Q3 2025
Reduced 59.24%
FDMT
4 D Molecular Therapeutics, Inc.
PUT
$106,000
12.6K
Q2 2025
Reduced 41.96%
ALXO
Alx Oncology Holdings Inc
CALL
$105,000
57.5K
Q1 2025
Reduced 94.05%
CVAC
Cure Vac N.V.
PUT
$105,000
19.6K
Q3 2025
New holding
VIR
Vir Biotechnology, Inc.
CALL
$105,000
18.5K
Q3 2025
Reduced 76.94%
NRIX
Nurix Therapeutics, Inc.
PUT
$104,000
11.3K
Q3 2025
Reduced 64.42%
SLS
Sellas Life Sciences Group, Inc.
PUT
$104,000
65.4K
Q3 2025
Added 128.67%
SPRO
Spero Therapeutics, Inc.
PUT
$103,000
54.8K
Q2 2025
Added 69.26%
APLT
Applied Therapeutics Inc.
PUT
$101,000
169K
Q2 2025
New holding
OVID
Ovid Therapeutics Inc.
CALL
$100,000
78.5K
Q3 2025
New holding
PEPG
Pep Gen Inc.
CALL
$98,000
21.4K
Q3 2025
New holding
VNDA
Vanda Pharmaceuticals Inc.
CALL
$98,000
19.7K
Q3 2025
Added 78.49%
AVIR
Atea Pharmaceuticals, Inc.
PUT
$91,000
31.4K
Q3 2025
New holding
AVIR
Atea Pharmaceuticals, Inc.
CALL
$90,000
31.1K
Q3 2025
New holding
VIR
Vir Biotechnology, Inc.
PUT
$90,000
15.9K
Q3 2025
Reduced 76.94%
ELDN
Eledon Pharmaceuticals, Inc.
PUT
$86,000
33.4K
Q2 2025
Added 62.2%
NKTX
Nkarta, Inc.
PUT
$84,000
40.7K
Q3 2025
Reduced 12.07%
ALDX
Aldeyra Therapeutics, Inc.
PUT
$80,000
15.5K
Q3 2025
Added 1122.53%
LTRN
Lantern Pharma Inc.
CALL
$80,000
18.4K
Q4 2024
Added 1645.8%
OVID
Ovid Therapeutics Inc.
PUT
$80,000
62.5K
Q3 2025
New holding
TSHA
Taysha Gene Therapies, Inc.
PUT
$80,000
25.7K
Q3 2025
Reduced 30.56%
ANVS
Annovis Bio, Inc.
PUT
$79,000
38.6K
Q3 2025
Added 494.51%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email